Vrije Universiteit Brussel

Vib Vzw

Boehringer Ingelheim International Gmbh

Université Grenoble Alpes

Centre Hospitalier Universitaire De Grenoble

Virje Universiteit Brussel

Université Joseph Fourier - Grenoble

Tony Lahoutte

Nick Devoogdt

Patrick De Baetselier

Geert Raes

Steve Schoonooghe

Jens De Vos

Jo Van Ginderachter

Damya Laoui

Matthias D'Huyvetter

Kiavash Movahedi

Sanjaya Singh

Alisa K Waterman

Cedric Jozef Néotère Ververken

Catherine Ghezzi

Daniel Fagret

Marleen Keyaerts

Alexis Broisat

Serge Muydermans

Matthias Schneider

Sophie Hernot

Gezim Bala

Simon Tierens

Matthias D'huyvetter

Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (V), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the V, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a γ-emitter and β-emitter.

Radiolabelled antibody fragments for use in treating cancer

The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V) or a functional fragment thereof, wherein said Vor a functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor, e.g. HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for detection, imaging, prognosis and diagnosis of cancer as well as for predicting patient response(s) to therapeutics.

Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response

Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (V), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the V, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a &#x3b3;-emitter and &#x3b2;-emitter.

The disclosure relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Targeting and in vivo imaging of tumor-associated macrophages

The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V) or functional fragments thereof, wherein said Vor functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g., HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for the prevention and/or treatment of cancer.

Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

The present invention relates to nanobodies specifically directed against VCAM-1 and to their use in medical imaging and in diagnostic, prognostic and treatment methods.

Anti-VCAM-1 nanobodies

The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.

CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease

The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques.

Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain

The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.

Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages

The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Growing community of inventors

Ganshoren, Belgium

Tony Lahoutte